A Phase 2 interventional study of SGX942 and Placebo in Oral Mucositis, sponsored by Soligenix. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.
Sponsored by Soligenix · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.
Among the 80 studies in Stomatitis with a site in United States, this one is the 16th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2013, is one of 33 in phase 2, and was the 34th registered.
307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.
Browse Stomatitis studies →12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:
UNCANCER LLC · Sites in United States
Ages 18+
Baptist Health South Florida · Sites in United States
Ages 18+
AstraZeneca · Sites in United States
Ages 18+
Woman's · Sites in United States
Ages 18+
NRG Oncology · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 35 · Phase 3 9 · Phase 4 4
First in 1999; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 60 across 277 interventional studies indexed under Stomatitis.
Median enrollment 60 across the 73 interventional studies, 22 across the 6 observational. Of the 60 that completed or were terminated, 26 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 80 have an industry lead sponsor. The 10 most frequent:
Soligenix is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Soligenix has 2 studies filed under Stomatitis — fewer than ten, so there is no comparison to draw.
8 of the studies in Stomatitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07290413Brigham and Women's HospitalPhotobiomodulation for the Prevention of Oral Mucositis | 2026-12 |
| NCT04805320University of NebraskaAssociation of Periodontal Inflammation on Immune Response in Wound Healing | 2027-01 |
| NCT06532279NRG OncologyTesting the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | 2027-01-01 |
| NCT07287826Woman'sUsing a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy | 2027-07 |
| NCT05966194EpicentRx, Inc.RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Stomatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control
Drug: Placebo
Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
Drug: SGX942
Duration of Severe Oral Mucositis (SOM)
Duration of SOM was defined as the number of days from the onset of SOM until resolution of SOM. If the patient did not meet the requirements for resolution of SOM by the 1-month follow up visit, he/she was considered censored at the 1-month follow-up visit (or point of discontinuation of the study, if the patient had discontinued prior to the end of planned treatment). Patients who did not experience SOM were assigned a duration of 0.01. OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4.
Time frame: 4 weeks after end of therapy
Residual Severe Oral Mucositis (SOM)
OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.
Time frame: 4 weeks after end of therapy
Duration of Severe Oral Mucositis (SOM)
OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.
Time frame: 4 weeks after end of therapy
Incidence of Clinically Reported, Non-fungal Infections
Time frame: 4 weeks after end of therapy
Percent of Patients With RECIST 1.1 Classification of "Complete Response"
The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions
Time frame: 4 weeks after end of therapy
Duration of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin
Time frame: 4 weeks after end of therapy
Incidence of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin
Time frame: 4 weeks after end of therapy
Survival
Time frame: 12 months after end of therapy
Percent of Patients With RECIST 1.1 Classification of "Complete Response"
The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions
Time frame: 12 months after end of therapy
| Milestone | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Started | 42 | 41 | 3 | 23 |
| Completed | 38 | 36 | 3 | 19 |
| Not completed | 4 | 5 | 0 | 4 |
Duration of SOM was defined as the number of days from the onset of SOM until resolution of SOM. If the patient did not meet the requirements for resolution of SOM by the 1-month follow up visit, he/she was considered censored at the 1-month follow-up visit (or point of discontinuation of the study, if the patient had discontinued prior to the end of planned treatment). Patients who did not experience SOM were assigned a duration of 0.01. OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4.
| days | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Duration of Severe Oral Mucositis (SOM) | 18 (5 to 36) | 9 (3 to 19) | 14 (0 to NA) | 22 (3 to 36) |
OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.
| percentage of participants | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Residual Severe Oral Mucositis (SOM) | 21 | 6 | 33 | 16 |
OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.
| WHO score * days | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Duration of Severe Oral Mucositis (SOM) | 35.5 (0 to 222) | 21.8 (0 to 210) | 33.0 (0 to 84) | 46.5 (0 to 167) |
| percentage of participants | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Incidence of Clinically Reported, Non-fungal Infections | 45 | 28 | 0 | 21 |
The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions
| percentage of participants | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Percent of Patients With RECIST 1.1 Classification of "Complete Response" | 39 | 47 | 33 | 21 |
| days | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Duration of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin | 30 (5 to 65) | 10 (0 to 19) | 14 (0 to NA) | 17 (0 to NA) |
| percentage of participants | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Incidence of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin | 82 | 67 | 67 | 80 |
| percentage of participants | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Survival | 81 | 93 | 100 | 83 |
The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions
| percentage of participants | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| Percent of Patients With RECIST 1.1 Classification of "Complete Response" | 53 | 53 | 33 | 53 |
Collected over From the time of enrollment up until four weeks (±5 days) following the last study drug treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 8/43 (18.6%) | 25/41 (61%) | 41/41 (100%) |
| 1.5 mg/kg | 3/41 (7.3%) | 25/42 (59.5%) | 42/42 (100%) |
| 3.0 mg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| 6.0 mg/kg | 4/24 (16.7%) | 16/23 (69.6%) | 23/23 (100%) |
| Event | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| DysphagiaGastrointestinal disorders | 2/41 | 1/42 | 1/3 | 0/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/41 | 0/42 | 0/3 | 3/23 |
| NauseaGastrointestinal disorders | 2/41 | 2/42 | 0/3 | 3/23 |
| VomitingGastrointestinal disorders | 4/41 | 3/42 | 0/3 | 0/23 |
| DehydrationMetabolism and nutrition disorders | 0/41 | 4/42 | 0/3 | 2/23 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/41 | 1/42 | 0/3 | 2/23 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/41 | 1/42 | 0/3 | 2/23 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/41 | 3/42 | 0/3 | 1/23 |
| ConstipationGastrointestinal disorders | 2/41 | 0/42 | 0/3 | 0/23 |
| Lobar pneumoniaInfections and infestations | 2/41 | 1/42 | 0/3 | 0/23 |
| Event | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg |
|---|---|---|---|---|
| DysphagiaGastrointestinal disorders | 11/41 | 14/42 | 3/3 | 6/23 |
| NauseaGastrointestinal disorders | 29/41 | 31/42 | 3/3 | 20/23 |
| Abdominal pain upperGastrointestinal disorders | 0/41 | 1/42 | 2/3 | 1/23 |
| ConstipationGastrointestinal disorders | 23/41 | 18/42 | 2/3 | 11/23 |
| Dry mouthGastrointestinal disorders | 11/41 | 14/42 | 2/3 | 7/23 |
| VomitingGastrointestinal disorders | 15/41 | 23/42 | 2/3 | 12/23 |
| ChillsGeneral disorders | 2/41 | 2/42 | 2/3 | 2/23 |
| FatigueGeneral disorders | 21/41 | 23/42 | 2/3 | 12/23 |
| Abnormal loss of weightMetabolism and nutrition disorders | 8/41 | 13/42 | 2/3 | 10/23 |
| DysgeusiaNervous system disorders | 11/41 | 22/42 | 2/3 | 13/23 |
| Age, Categorical(Participants) | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 31 | 31 | 2 | 20 | 84 |
| >=65 years | 11 | 10 | 1 | 3 | 25 |
| Sex: Female, Male(Participants) | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg | Total |
|---|---|---|---|---|---|
| Female | 9 | 9 | 2 | 3 | 23 |
| Male | 33 | 32 | 1 | 20 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 3 | 6 |
| Not Hispanic or Latino | 40 | 38 | 3 | 20 | 101 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 2 | 5 | 0 | 2 | 9 |
| White | 38 | 36 | 3 | 20 | 97 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | 1.5 mg/kg | 3.0 mg/kg | 6.0 mg/kg | Total |
|---|---|---|---|---|---|
| United States | 42 | 41 | 3 | 23 | 109 |
The record gives a start of Dec 2013, a primary completion of Dec 2015 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dusquetide
Soligenix